Status:
COMPLETED
What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol
Lead Sponsor:
University of Manchester
Collaborating Sponsors:
National Institute for Health Research, United Kingdom
Breast Cancer Now
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
NA
Brief Summary
This study aims to identify key benefits and harms of integrating risk stratification (the BC-Predict intervention) into the NHS Breast Screening Programme. A non-randomised fully counterbalanced stud...
Detailed Description
In principle, risk-stratification as a routine part of the NHS breast screening programme (NHS-BSP) should produce a better balance of benefits and harms. The main benefit is the offer of NICE (Nation...
Eligibility Criteria
Inclusion
- born biologically female,
- invited for either (a) first breast screening appointment (any age) or: (b) aged 57-63 years (only at East Cheshire and East Lancashire breast screening programmes),
- able to provide informed consent and complete a risk assessment questionnaire.
Exclusion
- previously has had breast cancer,
- has had bilateral mastectomy, or
- has previously participated in the related PROCAS (Predicting Risk Of Cancer At Screening) study
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
32298 Patients enrolled
Trial Details
Trial ID
NCT04359420
Start Date
August 1 2019
End Date
June 30 2022
Last Update
January 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manchester University NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom, M23 9LT